Genomictree Inc. (KOSDAQ:228760)

South Korea flag South Korea · Delayed Price · Currency is KRW
20,150
-600 (-2.89%)
Oct 10, 2025, 3:30 PM KST
-2.89%
Market Cap498.35B
Revenue (ttm)3.56B
Net Income (ttm)-9.10B
Shares Out24.02M
EPS (ttm)-379.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume127,091
Average Volume201,051
Open21,100
Previous Close20,750
Day's Range19,960 - 21,150
52-Week Range11,390 - 24,700
Beta0.12
RSI45.22
Earnings DateNov 10, 2025

About Genomictree

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 228760
Full Company Profile

Financial Performance

In 2024, Genomictree's revenue was 2.36 billion, a decrease of -30.89% compared to the previous year's 3.42 billion. Losses were -10.24 billion, 17.0% more than in 2023.

Financial Statements

News

There is no news available yet.